Immunotherapy Drugs Market Size to Surpass USD 217.34 BN by 2032
The immunotherapy drugs market size was estimated at USD 111.21 billion in 2022 and is expected to surpass around USD 217.34 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 6.93% during the forecast period 2023 to 2032.
Key Takeaways:
Immunotherapy Drugs Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 118.92 Billion |
| Market Size by 2032 | USD 217.34 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 6.93% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Drug type, Indication, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled |
Amgen, Inc.; Novartis AG; AbbVie, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche Ltd.; Johnson & Johnson Services, Inc.; AstraZeneca; GSK; Sanofi; Bayer AG |
The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.
For instance, in May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.
In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.
Indication Insights
On the basis of drug types, the industry has been further categorized into cancer, autoimmune diseases, infectious diseases, and others. The cancer segment accounted for the largest revenue share of more than 93.1% in 2022 owing to the increased prevalence of cancer, coupled with a rise in the launch of cancer immunotherapies. As per Globocan 2020, breast cancer and lung cancer are the two most predominant cancers with a prevalence of approximately 11.7% and 11.4%. Moreover, in April 2021, the FDA approved Opdivo (nivolumab) in combination with chemotherapy for patients with gastric cancer.
On the other hand, the autoimmune diseases segment is anticipated to register the fastest growth rate during the forecast period. The growth of this segment can be attributed to the increasing cases of autoimmune diseases across the globe and regional approvals of immunotherapy drugs. As per NCBI research, the estimated global prevalence of rheumatoid arthritis is around 0.46% of the global population. Moreover, GSK’s Benlysta (belimumab) received China’s National Medical Products Administration approval for the treatment of active lupus nephritis in February 2022.
Drug Type Insights
On the basis of drug types, the industry has been further divided into monoclonal antibodies, immunomodulators, and vaccines. The monoclonal antibodies segment accounted for the largest share of more than 78.10% in 2022 owing to increased R&D in therapeutic monoclonal antibodies coupled with supportive government initiatives. For instance, in May 2022, the U.S. FDA accepted the supplemental Biologics License Application for priority review of Dupixent (dupilumab) indicated for treating prurigo nodularis. The vaccines segment is expected to register the fastest CAGR during the forecast period.
The growth of this segment is attributed to strategic collaborations among key players and an increase in clinical trials for vaccine development. For instance, in January 2022, Pfizer Inc. and BioNTech SE entered a strategic collaboration to develop an mRNA-based vaccine to prevent shingles. Under this agreement, BioNTech’s mRNA platform technology and Pfizer’s antigen technology will be utilized. In addition, in March 2022, the National Institute of Health launched a Phase 1 trial of three investigational HIV mRNA-based vaccines.
Regional Insights
North America dominated the global industry in 2022 and accounted for the largest share of more than 46.16% of the overall revenue. The launch and regulatory approval of new immunotherapy drugs and favorable reimbursement policies are projected to aid in the region’s growth. For instance, Keytruda, Merck’s anti-PD-1 therapy, was approved by the FDA in October 2021, in combination with chemotherapy for cervical cancer treatment. Moreover, in August 2021, Opdivo (nivolumab) manufactured by Bristol Myers Squibb Co. received FDA approval for the treatment of urothelial carcinoma.
The Centers for Medicare & Medicaid Services provides reimbursement for hospital inpatient treatment with chimeric antigen receptor T-cell therapy. Japan is expected to witness a significant CAGR during the forecast period. The increasing prevalence of cancer in Japan, rising geriatric population, increasing investments in medical research, and well-developed healthcare infrastructure, are some of the major factors boosting the region’s growth. According to the GLOBOCAN report, in 2020, around 27,10,728 people were suffering from cancer in Japan, with about 10,28,658 newly diagnosed cancer cases. Thus, the demand for advanced immunotherapies is expected to be high in this region.
Key Companies & Market Share Insights
The leading players are focusing on growth strategies, such as innovations in the existing products, approval of new products, and mergers & acquisitions, to gain higher market shares. For instance, in January 2021, Sanofi entered an agreement with Kymab to acquire the company for an upfront payment of about USD 1.1 billion, resulting in the addition of KY1005, a monoclonal antibody, into its pipeline. Some of the prominent players in the global immunotherapy drugs market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Immunotherapy Drugs market.
By Drug Type
By Indication
By Region
Chapter 1 Methodology and Scope
1.1 Market segmentation
1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 Nova one advisor internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.6 List of primary sources
1.4 Information or data analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Regulatory framework
3.3 Penetration and Growth Prospect Mapping
3.4 Pipeline Analysis
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.2 Market restraint analysis
3.6 PESTEL Analysis
Chapter 4 Global Immunotherapy Drugs Market - Segment Analysis, By Drug Type, 2020 - 2032
4.1 Global Immunotherapy Drugs Market: Drug Type Movement Analysis
4.2 Monoclonal Antibodies
4.2.1 Monoclonal antibodies market estimates and forecast, 2020 - 2032
4.3 Immunomodulators
4.3.1 Immunomodulators market estimates and forecast, 2020 - 2032
4.4 Vaccine
4.4.1 Vaccine market estimates and forecast, 2020 - 2032
Chapter 5 Global Immunotherapy Drugs Market - Segment Analysis, By Indication, 2020 - 2032
5.1 Global Immunotherapy Drugs Market: Indication Movement Analysis
5.2 Cancer
5.2.1 Cancer market estimates and forecast, 2020 - 2032
5.3 Autoimmune Diseases
5.3.1 Autoimmune diseases market estimates and forecast, 2020 - 2032
5.4 Infectious Diseases
5.4.1 Infectious diseases market estimates and forecast, 2020 - 2032
5.5 Others
5.5.1 Others market estimates and forecast, 2020 - 2032
Chapter 6 Immunotherapy Drugs Market: Segment Analysis, by Region, 2020 - 2032
6.1 Immunotherapy Drugs Market: Regional Movement Analysis
6.1.1 North America
6.1.1.1 North America market estimates and forecast, 2020 - 2032
6.1.1.2 U.S.
6.1.1.2.1 U.S. market estimates and forecast, 2020 - 2032
6.1.1.3 Canada
6.1.1.3.1 Canada market estimates and forecast, 2020 - 2032
6.1.2 Europe
6.1.2.1 Europe market estimates and forecast, 2020 - 2032
6.1.2.2 U.K.
6.1.2.2.1 U.K. market estimates and forecast, 2020 - 2032
6.1.2.3 Germany
6.1.2.3.1 Germany market estimates and forecast, 2020 - 2032
6.1.2.4 France
6.1.2.4.1 France market estimates and forecast, 2020 - 2032
6.1.2.5 Spain
6.1.2.5.1 Spain market estimates and forecast, 2020 - 2032
6.1.2.6 Italy
6.1.2.6.1 Italy market estimates and forecast, 2020 - 2032
6.1.2.7 Russia
6.1.2.9.1 Russia market estimates and forecast, 2020 - 2032
6.1.3 Asia Pacific
6.1.3.1 Asia Pacific market estimates and forecast, 2020 - 2032
6.1.3.2 Japan
6.1.3.2.1 Japan market estimates and forecast, 2020 - 2032
6.1.3.3 China
6.1.3.3.1 China market estimates and forecast, 2020 - 2032
6.1.3.4 India
6.1.3.4.1 India market estimates and forecast, 2020 - 2032
6.1.3.5 Australia
6.1.3.5.1 Australia market estimates and forecast, 2020 - 2032
6.1.3.5 South Korea
6.1.3.5.1 South Korea market estimates and forecast, 2020 - 2032
6.1.3.6 Singapore
6.1.3.6.1 Singapore market estimates and forecast, 2020 - 2032
6.1.4 Latin America
6.1.4.1 Latin America market estimates and forecast, 2020 - 2032
6.1.4.2 Brazil
6.1.4.2.1 Brazil market estimates and forecast, 2020 - 2032
6.1.4.3 Mexico
6.1.4.3.1 Mexico market estimates and forecast, 2020 - 2032
6.1.4.4 Argentina
6.1.4.4.1 Argentina market estimates and forecast, 2020 - 2032
6.1.5 Middle East & Africa
6.1.5.1 Middle East & Africa market estimates and forecast, 2020 - 2032
6.1.5.2 South Africa
6.1.5.2.1 South Africa market estimates and forecast, 2020 - 2032
6.1.5.3 Saudi Arabia
6.1.5.3.1 Saudi Arabia market estimates and forecast, 2020 - 2032
6.1.5.5 United Arab Emirates
6.1.5.5.1 United Arab Emirates market estimates and forecast, 2020 - 2032
Chapter 7 Global Immunotherapy Drugs Market: Competitive Analysis
7.1 Recent Developments and Impact Analysis, by Key Market Participants
7.1.1 Major deals & strategic alliances analysis
7.1.1.1 New Product Launches
7.1.1.2 Mergers and Acquisitions
7.1.1.3 Partnerships & Agreements
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.2.3 Emerging Players
7.2.4 Heat Map Analysis
7.3 Company Market Position Analysis
7.4 Vendor Landscape
7.4.1 List of Key Distributors and Channel Partners
7.4.2 List of Potential End Users
7.4.3 Key Company Market Share Analysis, 2021
7.5 Company Market Share, 2021
7.5.1 Competitive Dashboard Analysis
7.6 Private Companies
7.6.1 List of Key Emerging Companies
7.6.2 Regional Network Map
7.7 Company Profiles
7.7.1 Amgen, Inc.
7.7.1.1 Company overview
7.7.1.2 Financial performance
7.7.1.3 Product benchmarking
7.7.1.4 Strategic initiatives
7.7.2 Novartis AG
7.7.2.1 Company overview
7.7.2.2 Financial performance
7.7.2.3 Product benchmarking
7.7.2.4 Strategic initiatives
7.7.3 AbbVie, Inc.
7.7.3.1 Company overview
7.7.3.2 Financial performance
7.7.3.3 Product benchmarking
7.7.3.4 Strategic initiatives
7.7.4 Pfizer, Inc.
7.7.4.1 Company overview
7.7.4.2 Financial performance
7.7.4.3 Product benchmarking
7.7.4.4 Strategic initiatives
7.7.5 F. Hoffmann-La Roche Ltd.
7.7.5.1 Company overview
7.7.5.2 Financial performance
7.7.5.3 Product benchmarking
7.7.5.4 Strategic initiatives
7.7.6 Johnson & Johnson Services, Inc.
7.7.6.1 Company overview
7.7.6.2 Product benchmarking
7.7.6.3 Strategic initiatives
7.7.7 AstraZeneca
7.7.7.1 Company overview
7.7.7.2 Financial performance
7.7.7.3 Product benchmarking
7.7.8 GSK
7.7.7.1 Company overview
7.7.7.2 Financial performance
7.7.7.3 Product benchmarking
7.7.7.4 Strategic initiatives
7.7.9 Sanofi
7.7.9.1 Company overview
7.7.9.2 Financial performance
7.7.9.3 Product benchmarking
7.7.9.4 Strategic initiatives
7.7.10 Bayer AG
7.7.7.1 Company overview
7.7.7.2 Financial performance
7.7.7.3 Product benchmarking
7.7.7.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers